Answers are grounded in this paper and cite their sources.
We confirm acceptable toxicity and excellent disease control in patients with AP-IMT treated with crizotinib, which may be ceased without recurrence in most. Relapses occurred in two of three patients with RANBP2-ALK translocated IMT, which suggests that such patients require additional therapy.
No takes yet. Share an insight, caveat, or question.
Trahair et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: